Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Status:
RECRUITING
Trial end date:
2029-06-21
Target enrollment:
Participant gender:
Summary
This is a prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab a in untreated marginal zone lymphoma. It is planned to recruit 45 patients. The primary endpoint is the complete remission rate at 12 months.
Phase:
PHASE2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China